why choose us

First received: October 03, 2022

Clinical Trial: A Study in Participants With Non-cirrhotic NASH With Fibrosis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

Study Type: INTERVENTIONAL


Official Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With Non-cirrhotic Non-alcoholic Steatoh

Brief Summary: This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial.Participants will be in the trial for up to 24 weeks, including a screening period lasting up to 8 weeks, a 12-week treatment period, and a 4-week safety follow-up periodParticipants are not expected to directly benefit from treatment during this trial.Participants will help researchers learn more about and how to develop AZD4831 to treat NASH.

Read more